dcc-3116,vimseltinib
deciphera
['dcc-3116 ', 'vimseltinib', 'dcc-3116', 'deciphera']
today, we shared updated phase 1/2 data for vimseltinib, our investigational inhibitor of csf1r, at #esmo2022. join us today at 7:30am et / 1:30pm cest for a live call on our dcc-3116 &amp; vimseltinib clinical programs. learn about our vimseltinib data here: 
Deciphera is a biopharmaceutical company focused on discovering, developing & commercializing important new medicines to improve the lives of people with cancer